Abstract
Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents.
Document Type
Review
Publication Date
8-28-2015
Digital Object Identifier (DOI)
http://dx.doi.org/10.1186/s13569-015-0035-x
Funding Information
This work was supported by DanceBlue, an effort of the University of Kentucky student community to support pediatric oncology care and research.
Repository Citation
Wagner, Lars M., "Fifteen Years of Irinotecan Therapy for Pediatric Sarcoma: Where to Next?" (2015). Pediatrics Faculty Publications. 167.
https://uknowledge.uky.edu/pediatrics_facpub/167
Notes/Citation Information
Published in Clinical Sarcoma Research, v. 5, article 20, p. 1-7.
© 2015 Wagner.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated.